Compare DraftKings Inc (DKNG) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance

DraftKings IncTrade

Royalty Pharma plc Class A Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

DraftKings Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? DraftKings Inc trades at $19.94 (market cap $9.86B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.52 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 2.6× DraftKings Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.

	DKNG	RPRX
Market Cap	$9.86B	$25.27B
Volume	16,584,596	3,671,183
Sector	Consumer Cyclical	Health
52-Week High	$36.24	$63.96
52-Week Low	$18.59	$35.44
Typical Hold Time	55 Days	0 Days
Enterprise Value	$10.80B	$32.50B
Dividend Yield	—	1.66%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DraftKings Inc

DraftKings (DKNG) trades at $19.15, down 3.04% and near its 52-week low of $18.95. The stock is technically bearish with weak moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue grew to $6.05B in 2025 with a slight net profit of $3.71M, but recent quarters show earnings misses. The company is investing in prediction markets and maintains a $1B EBITDA target for 2026.

Despite a high valuation (P/E 246.33) and recent price decline, 75% of analysts rate DKNG a Buy with a $33.13 consensus target. Key risks include competitive pressure, regulatory uncertainty, and the stock's sensitivity to growth expectations. The path to sustained profitability and margin expansion remains critical for investor confidence.

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DKNG

No sentiment data available yet.

RPRX

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

DKNG

DraftKings shares drop 19% in a month; Bank of America upgrades to Buy, signaling a possible bottom.24/7 Wall Street · 22 hours agoNeutral BofA upgrades DraftKings to 'Buy' citing growth in prediction markets and 45% upside potential.Proactive Investors · 3 days agoBullish Nasdaq hits record high driven by growth stocks despite cautious Dow and rising long-term yieldsFXEmpire · 4 days agoBullish View details →

RPRX

Royalty Pharma to release Q3 2026 earnings on Nov 4 with live webcast and call.GlobeNewsWire · 5 hours agoNeutral View details →

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.